STAR Therapeutics

STAR Therapeutics is a clinical-stage biotechnology company founded in 2018 by Adam Rosenthal, PhD, and headquartered in South San Francisco, California. The company discovers and develops best-in-class antibody therapies to transform the lives of patients with serious diseases. STAR's distinctive pipeline is built on novel biology that enables a pipeline-in-a-product strategy, with lead program VEGA focused on von Willebrand disease (VWD) and other bleeding disorders. VGA039, the company's lead antibody candidate, has received FDA Rare Pediatric Disease and Breakthrough Therapy Designations for VWD prophylaxis and is currently in Phase 3 clinical evaluation. The leadership team brings deep expertise having previously invented four first-in-class antibodies, including ENJAYMO — the first approved therapy for cold agglutinin disease. STAR is backed by prominent life sciences investors including OrbiMed, Redmile Group, and Sofinnova Investments.